APACHE: An open label, randomized, phase 2 study of the anti-programmed death-ligand 1 (PD-L1) durvalumab (D, MEDI4736), alone or in combination with tremelimumab (T), in patients (pts) with advanced germ cell tumors (GCT)

被引：0
|
作者：
Necchi, A. [1 ]
Mariani, L. [2 ]
Anichini, A. [3 ]
Giannatempo, P. [1 ]
Raggi, D. [1 ]
Togliardi, E. [4 ]
Calareso, G. [5 ]
Di Genova, N. [1 ]
Crippa, F. [6 ]
Salvioni, R. [7 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Med Oncol, Milan, Italy
[2] Fdn IRCCS Ist Nazl Tumori, Clin Epidemiol & Trials Org Unit, Milan, Italy
[3] Fdn IRCCS Ist Nazl Tumori, Expt Oncol & Mol Med, Milan, Italy
[4] Fdn IRCCS Ist Nazl Tumori, Pharm Unit, Milan, Italy
[5] Fdn IRCCS Ist Nazl Tumori, Radiol, Milan, Italy
[6] Fdn IRCCS Ist Nazl Tumori, Nucl Med & PET Unit, Milan, Italy
[7] Fdn IRCCS Ist Nazl Tumori, Surg Oncol, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw373.73
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
846TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC).
    Creelan, Ben C.
    Chow, Laura Q.
    Kim, Dong-Wan
    Kim, Sang-We
    Yeh, Tammie
    Karakunnel, Joyson Joseph
    Gibbons, Don Lynn
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [22] A phase II study of the anti-programmed death ligand-1 antibody durvalumab (D; MEDI4736) in combination with PARP inhibitor, olaparib (O), in metastatic castration-resistant prostate cancer (mCRPC).
    Karzai, Fatima
    Madan, Ravi Amrit
    Owens, Helen
    Hankin, Amy
    Couvillon, Anna
    Houston, Nicole D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [23] A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of MEDI9447 alone and in combination with durvalumab (MEDI4736) in patients with advanced solid tumors
    Bendell, Johanna C.
    Reddy, Vijay
    Tavakkoli, Fatemeh
    Leow, Ching Ching
    Li, Xia
    Kumar, Rakesh
    Strickler, John H.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] A Phase III Study of MEDI4736 (M) an Anti-PD-L1 Antibody ± Tremelimumab (T), vs Standard of Care (SoC), in Patients with Advanced NSCLC (ARCTIC)
    Planchard, David
    Shtivelband, Mikhail
    Levy, Benjamin P.
    Hussein, Maen
    Shi, Kelvin
    Ibrahim, Ramy
    Ballas, Marc
    Soria, Jean-Charles
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S429 - S429
  • [25] Phase 1/2 Study of Mocetinostat and Durvalumab (MEDI4736) in Patients with Advanced Solid Tumors and Non Small Cell Lung Cancer (NSCLC)
    Haigentz, Missak
    Nemunaitis, John
    Johnson, Melissa
    Mohindra, Nisha
    Eaton, Keith
    Patel, Manish
    Awad, Mark
    Faltaos, Demiana
    Chen, Isan
    Christensen, James
    Potvin, Diane
    Neskorik, Tavette
    Levisetti, Matteo
    Garon, Edward
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1073 - S1074
  • [26] A phase 1b open-label study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in subjects with advanced non-small cell lung cancer.
    Pinder, Mary Colleen
    Rizvi, Naiyer A.
    Goldberg, Sarah B.
    Balmanoukian, Ani Sarkis
    Narwal, Ralesh
    Robbins, Paul B.
    D'Angelo, Gina
    Blake-Haskins, Andy
    Karakunnel, Joyson Joseph
    Antonia, Scott Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] Phase 1 study of MEDI4736, an anti-PD-L1 antibody, in combination with dabrafenib and trametinib or trametinib alone in patients with unresectable or metastatic melanoma
    Gordon, Michael S.
    Lutzky, Jose
    Lawrence, Donald P.
    Orford, Keith W.
    Blake-Haskins, Andy
    Di Pietro, Alessandra
    Robbins, Paul B.
    Dar, Mohammed M.
    Ribes, Antoni
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] A phase Ia/Ib trial of the anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumours or lymphomas
    Shen, L.
    Li, J.
    Xu, N.
    Xing, B.
    Zhang, Q.
    Zhao, Y.
    Cao, J.
    Ding, J.
    Wang, J.
    Wang, Y.
    Dai, H.
    ANNALS OF ONCOLOGY, 2019, 30 : 516 - 516
  • [29] Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
    Rizvi, Hira
    Sanchez-Vega, Francisco
    La, Konnor
    Chatila, Walid
    Jonsson, Philip
    Halpenny, Darragh
    Plodkowski, Andrew
    Long, Niamh
    Sauter, Jennifer L.
    Rekhtman, Natasha
    Hollmann, Travis
    Schalper, Kurt A.
    Gainor, Justin F.
    Shen, Ronglai
    Ni, Ai
    Arbour, Kathryn C.
    Merghoub, Taha
    Wolchok, Jedd
    Snyder, Alexandra
    Chaft, Jamie E.
    Kris, Mark G.
    Rudin, Charles M.
    Socci, Nicholas D.
    Berger, Michael F.
    Taylor, Barry S.
    Zehir, Ahmet
    Solit, David B.
    Arcila, Mina E.
    Ladanyi, Marc
    Riely, Gregory J.
    Schultz, Nikolous
    Hellmann, Matthew D.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (07) : 633 - +
  • [30] Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody: A phase 1, open-label study in advanced malignancies
    Hamid, O.
    Chow, L. Q.
    Sanborn, R. E.
    Marshall, S.
    Black, C.
    Gribbin, M.
    McDevitt, J.
    Karakunnel, J. J.
    Gray, J. E.
    ANNALS OF ONCOLOGY, 2016, 27
12345